Results 11 to 20 of about 3,949,650 (302)
Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism
Molecular Psychiatry, 2021 Midbrain dopamine neurons deteriorate in Parkinson’s disease (PD) that is a progressive neurodegenerative movement disorder. No cure is available that would stop the dopaminergic decline or restore function of injured neurons in PD. Neurotrophic factors (
P. Lindholm, M. Saarma
semanticscholar +1 more source
Restless Legs Syndrome Among the Elderly
International Journal of Gerontology, 2009 Restless legs syndrome is a sleep and movement disorder that affects 5–15% of the general population, with an increased prevalence among the elderly population.
Pei-Hao Chen, Shih-Jung Cheng
doaj +1 more source
Biomedicines, 2023 Treatment resistant schizophrenia (TRS) is characterized by a lack of, or suboptimal response to, antipsychotic agents. The biological underpinnings of this clinical condition are still scarcely understood.
Felice Iasevoli +8 more
doaj +1 more source
Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions
Frontiers in Neurology, 2013 Modafinil, in its two clinical formulations (Provigil® and Nuvigil®), is a widely prescribed wake-promoting therapeutic agent. It binds competitively to the cell membrane dopamine transporter and is dependent on catecholaminergic (dopaminergic ...
Jonathan P Wisor
doaj +1 more source
F1000Research, 2018 Dopamine is a key neurotransmitter, and is widely used as a central nervous system (CNS) agent. Dopamine plays an important role in humans, including a major role in reward and motivation behaviour.
Aman Kundu, Gyanesh Singh
doaj +1 more source
The dopamine hypothesis of drug addiction and its potential therapeutic value.
Frontiers in Psychiatry, 2011 Dopamine (DA) transmission is deeply affected by drugs of abuse, and alterations in DA function are involved in various phases of drug addiction and potentially exploitable therapeutically.
Marco eDiana
doaj +1 more source
International journal of clinical practice, 2015 In prior 15-min challenges, we tackled the three new anorectic agents (1) and three new antidepressant medications (2). This time we will sort out three dopamine receptor partial agonists, one old (aripiprazole, commercialised in 2002, and now available ...
L. Citrome
semanticscholar +1 more source
Research Progress of PET Molecular Probes Targeting Dopamine D3 Receptor
Journal of Isotopes, 2023 Dopamine D3 receptors are closely related to drug addiction, Parkinson’s disease (PD), schizophrenia and other neuropsychiatric diseases. PET imaging agents that target dopamine D3 receptors can noninvasively show changes in receptor density and status ...
ZHANG Ge, XUE Jingquan, ZHAO Shilun, LIU Yu, YANG Wenjiang
doaj
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
PLoS ONE, 2014 ObjectiveTherapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of ...
Sachiko Nakaoka +6 more
doaj +1 more source
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2022 Gastrointestinal (GI) prokinetic agents are drugs that increase GI motility and promote the movement of contents in the GI tract by amplifying and controlling the contraction of GI smooth muscle.
Hyo Yeop Song +2 more
doaj +1 more source